All about Drugs Live by Dr Anthony Melvin Crasto
Viltolarsen 维托拉生 ビルトラルセン Formula C244H381N113O88P20 CAS 2055732-84-6 Mol weight 6924.8155 APPROVED FDA 2020/8/12, Viltepso APPROVED JAPAN PMDA 2020/3/25, VILTEPSO NCNP-01 NS-065 NS-065/NCNP-01 WHO 10771 WHO-10771 NAME DOSAGE STRENGTH ROUTE LABELLER MARKETING START MARKETING END Viltepso Injection, solution 250 mg/1 Intravenous Ns Pharma, Inc. 2020-08-13 Not applicable SYN Watanabe N, Nagata T, Satou Y, Masuda S, Saito T, …
Pemigatinib INCB054828 Formula C24H27F2N5O4 CAS 1513857-77-6 2379919-96-5 HCL Mol weight 487.4991 2020/4/17FDA APPROVED, PEMAZYRE 佩米替尼 [Chinese] [INN] 3-(2,6-Difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholinomethyl)-1,3,4,6-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one 2H-Pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-8-(4-morpholinylmethyl)- 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one OriginatorIncyte Corporation DeveloperIncyte Corporation; Innovent Biologics ClassAntineoplastics; Ethers; Fluorobenzenes; Morpholines; Pyridines; Pyrimidinones; Pyrroles; Small molecules Mechanism of ActionType 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth …
EIDD 2801, Molnupiravir Molecular Formula: C13H19N3O7 Molecular Weight: 329.31 g/mol CAS 2349386-89-4 [(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl 2-methylpropanoate UNII YA84KI1VEW Molnupiravir (development codes MK-4482 and EIDD-2801) is an experimental antiviral drug which is orally active (can be taken orally) and was developed for the treatment of influenza. It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through introduction of copying errors during viral …
Keoxifene hydrochloride, Raloxifene hydrochloride, LY-139481(free base), LY-156758, Optruma, Loxifen, Evista Title: Raloxifene CAS Registry Number: 84449-90-1 CAS Name: [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Additional Names: keoxifene Manufacturers’ Codes: LY-139481 Molecular Formula: C28H27NO4S Molecular Weight: 473.58 Percent Composition: C 71.01%, H 5.75%, N 2.96%, O 13.51%, S 6.77% Literature References: Nonsteroidal, selective estrogen receptor modulator (SERM). Prepn: C. D. Jones, EP 62503; idem, US 4418068 (1982, 1983 both to Lilly); idem et al., J. Med. Chem. 27, 1057 (1984). Review …
Tucatinib ツカチニブ; N6-(4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl)-N4-(3-methyl-4-{[1,2,4]triazolo[1,5-a]pyridin-7-yloxy}phenyl)quinazoline-4,6-diamine Formula C26H24N8O2 CAS 937263-43-9 Mol weight 480.5212 To treat advanced unresectable or metastatic HER2-positive breast cancer Drug Trials Snapshot FDA APPROVED 4/17/2020 Tukysa ARRY 380 ARRY-380 ONT 380 ONT-380 Tucatinib (INN),[1] sold under the brand name Tukysa, is a small molecule inhibitor of HER2 for the treatment of HER2-positive breast cancer.[2][3] It was developed by Array BioPharma and licensed to Cascadian Therapeutics …
Ripretinib リプレチニブ; Formula C24H21BrFN5O2 CAS 1442472-39-0 Mol weight 510.3582 Antineoplastic, Receptor tyrosine kinase inhibitor US FDA APPROVED 2020/5/15 QUINLOCK NAME DOSAGE STRENGTH ROUTE LABELLER MARKETING START MARKETING END Qinlock Tablet 50 mg Oral Deciphera Pharmaceuticals. Llc Not applicable Not applicable Qinlock Tablet 50 mg/1 Oral Deciphera Pharmaceuticals, LLC 2020-05-15 Not applicable SYN Ripretinib, sold under the …
REPROXALAP レプロキサラップ; ADX-102 2-(3-amino-6-chloroquinolin-2-yl)propan-2-ol C12H13ClN2O, 236.7 g/mol CAS 916056-79-6 UNII-F0GIZ22IJH 2-(3-amino-6-chloroquinolin-2-yl)propan-2-ol Phase 3 Clinical Aldeyra Therapeutics is developing reproxalap, which binds and traps free aldehydes, formulated using Captisol technology licensed from Ligand Pharmaceuticals as an eye drop formulation, for treating acute noninfectious anterior uveitis, allergic conjunctivitis and dry eye syndrome. PATENT product case, WO2006127945 , EU …
Lercanidipine CAS Registry Number: 100427-26-7 CAS Name: 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester Additional Names: methyl 1,1,N-trimethyl-N-(3,3-diphenylpropyl)-2-aminoethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate; methyl 1,1-dimethyl-2-[N-(3,3-diphenylpropyl)-N-methylamino]ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; masnidipine Molecular Formula: C36H41N3O6 Molecular Weight: 611.73 Percent Composition: C 70.68%, H 6.76%, N 6.87%, O 15.69% Literature References: Dihydropyridine calcium channel blocker. Prepn: D. Nardi et al., EP 153016; eidem, US 4705797 (1985, 1987 both to Recordati). Pharmacology: G. Bianchi et al., Pharmacol. Res. 21, 193 (1989). Clinical evaluation in hypertension: E. …
Spinosad Spinosyn A: The chemical name is: 1H-as-Indaceno[3,2- d]oxacyclododecin-7,a5-dione, 2-[(6-deoxy-2,3,4-tri-O-methyl-alphaL-mannopyranosyl)oxy]-13-[[2R,5S,6R)-5-(dimethylamino) tetrahydro-6-methyl-2H-pyran-2-yl]oxy]-9-ethyl2,3,3a,5a,5b,6,9,10,11,12,13,14,16a,16b-tetradecahydro-14-metyl-, (2R,3aS,5aR,5bS,9S,13S,14R,16aS,16bR)- Spinosyn D: The chemical name is: 1H-as-Indaceno[3,2- d]oxacyclododecin-7,15-dione, 2-[(6-deoxy-2,3,4-tri-O-methyl-alphaL-mannopyranosyl)oxy]-13-[[2R,5S,6R)-5-(dimethylamino) tetrahydro-6-methyl-2H-pyran-2-yl]oxy]-9-ethyl2,3,3a,5a,5b,6,9,10,11,12,13,14,16a,16b-tetradecahydro-4,14-dimetyl-, (2S,3aSR,5aS,5bS,9S,13S,14R,16aS,16bS)- 168316-95-8 Molecular FormulaC83H132N2O20 Average mass1477.938 Da Comfortis Conserve EC 434-300-1 Natroba NaturaLyte Spinosad Tracer Tracer Naturalyte UNII-XPA88EAP6V XDE 105 Natroba (Spinosad) Suspension 0.9% ParaPro Pharma New Drug Application (NDA): 022408 appr 01/18/2011 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022408Orig1s000ChemR.pdf spinosad, …
Triheptanoin Approved US FDA 30/6/2020 Dojolvi UX 007 Triheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation.4 In clinical trials, patients with long chain fatty acid oxidation disorders (lc-FAODs) treated with triheptanoin are less likely to develop hypoglycemia, cardiomyopathy, rhabdomyolysis, and hepatomegaly.1,2 Complications in lc-FAOD …